STL Index for: Mohamad R. Taha
A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis
Upadacitinib shows sustained long-term efficacy and safety for moderate-to-severe atopic dermatitis in 76-week studies. The oral JAK inhibitor maintains 80%+ EASI-75 response rates with manageable side effects, outperforming dupilumab in head-to-head trials while offering faster symptom relief for chronic eczema patients.
Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis
Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.
A Review of the Role and Treatment of Biofilms in Skin Disorders
Learn about the role of biofilms in skin disorders like acne, atopic dermatitis, and chronic wounds. This article explores how biofilms contribute to disease pathogenesis, their resistance to antibiotics, and the latest conventional and innovative treatments aimed at targeting biofilm-associated skin conditions.
